{"id":"https://openalex.org/W3150895131","doi":null,"title":"Neue Entwicklungen in der Pharmakotherapie der Herzinsuffizienz // New aspects of pharmacotherapy in heart failure","display_name":"Neue Entwicklungen in der Pharmakotherapie der Herzinsuffizienz // New aspects of pharmacotherapy in heart failure","alternate_titles":[],"publication_year":2021,"publication_date":"2021-04-01","ids":{"openalex":"https://openalex.org/W3150895131","mag":"3150895131"},"language":"de","primary_location":{"id":"pmh:oai:kup.at:14911","doi":null,"is_oa":true,"landing_page_url":"http://www.kup.at/kup/pdf/14911.pdf","pdf_url":"http://www.kup.at/kup/pdf/14911.pdf","source":{"id":"https://openalex.org/S4306402201","display_name":"Journal f\u00fcr Kardiologie (Krause & Pachernegg GmbH)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"application/pdf"},"parent_works":[],"lineage":["https://openalex.org/W3150895131"],"child_works_count":0,"type":"other","is_traditional":false,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://www.kup.at/kup/pdf/14911.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064044633","display_name":"Moritz Messner","orcid":"https://orcid.org/0000-0003-3250-4353","observed_orcids":["https://orcid.org/0000-0003-3250-4353"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Moritz Messner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5077870174","display_name":"Mm Zaruba","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mm Zaruba","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"3","first_page":"104","last_page":"108"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13381","display_name":"Heart rate and cardiovascular health","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/heart-failure","display_name":"heart failure","score":0.972000002861023},{"id":"https://openalex.org/keywords/heart-failure-with-reduced-ejection-fraction","display_name":"heart failure with reduced ejection fraction","score":0.9020000100135803},{"id":"https://openalex.org/keywords/heart-failure-with-preserved-ejection-fraction","display_name":"heart failure with preserved ejection fraction","score":1.0},{"id":"https://openalex.org/keywords/drug-therapy","display_name":"pharmacotherapy","score":0.8569999933242798},{"id":"https://openalex.org/keywords/sacubitril-valsartan","display_name":"sacubitril/valsartan","score":0.9700000286102295},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.890999972820282},{"id":"https://openalex.org/keywords/dapagliflozin","display_name":"dapagliflozin","score":0.9710000157356262},{"id":"https://openalex.org/keywords/empagliflozin","display_name":"empagliflozin","score":0.9950000047683716},{"id":"https://openalex.org/keywords/omecamtiv-mecarbil","display_name":"omecamtiv mecarbil","score":0.9879999756813049},{"id":"https://openalex.org/keywords/vericiguat","display_name":"vericiguat","score":0.9980000257492065},{"id":"https://openalex.org/keywords/advanced-heart-failure","display_name":"advanced heart failure","score":0.6510000228881836},{"id":"https://openalex.org/keywords/transthyretin-amyloidosis","display_name":"transthyretin amyloidosis","score":0.9110000133514404},{"id":"https://openalex.org/keywords/tafamidis","display_name":"tafamidis","score":0.996999979019165},{"id":"https://openalex.org/keywords/ace-inhibitors","display_name":"ACE inhibitors","score":0.6650000214576721},{"id":"https://openalex.org/keywords/beta-blockers","display_name":"beta-blockers","score":0.9629999995231628},{"id":"https://openalex.org/keywords/mineralocorticoid-receptor-antagonists","display_name":"mineralocorticoid receptor antagonists","score":0.9959999918937683},{"id":"https://openalex.org/keywords/hospitalization","display_name":"hospitalization","score":0.6539999842643738}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6392288208007812},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.4593394994735718},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.4398949146270752},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18735215067863464}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:oai:kup.at:14911","doi":null,"is_oa":true,"landing_page_url":"http://www.kup.at/kup/pdf/14911.pdf","pdf_url":"http://www.kup.at/kup/pdf/14911.pdf","source":{"id":"https://openalex.org/S4306402201","display_name":"Journal f\u00fcr Kardiologie (Krause & Pachernegg GmbH)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"application/pdf"},{"id":"mag:3150895131","doi":null,"is_oa":false,"landing_page_url":"https://www.kup.at/kup/pdf/14911.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S2764661020","display_name":"Journal f\u00fcr Kardiologie","issn_l":"1024-0098","issn":["1024-0098"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["poland-20"],"host_organization":"https://openalex.org/P4310317876","host_organization_name":"Krause & Pachernegg GmbH","host_organization_lineage":["https://openalex.org/P4310317876"],"host_organization_lineage_names":["Krause & Pachernegg GmbH"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Journal fu\u0308r Kardiologie","raw_type":null}],"best_oa_location":{"id":"pmh:oai:kup.at:14911","doi":null,"is_oa":true,"landing_page_url":"http://www.kup.at/kup/pdf/14911.pdf","pdf_url":"http://www.kup.at/kup/pdf/14911.pdf","source":{"id":"https://openalex.org/S4306402201","display_name":"Journal f\u00fcr Kardiologie (Krause & Pachernegg GmbH)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"application/pdf"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3150895131.pdf","grobid_xml":"https://content.openalex.org/works/W3150895131.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W1964714332","https://openalex.org/W2050856345","https://openalex.org/W2113698123","https://openalex.org/W2136642260","https://openalex.org/W2150959326","https://openalex.org/W2163340573","https://openalex.org/W2163584170","https://openalex.org/W2169077241","https://openalex.org/W2187526770","https://openalex.org/W2397911846","https://openalex.org/W2790015075","https://openalex.org/W2790275265","https://openalex.org/W2888036721","https://openalex.org/W2899841238","https://openalex.org/W2944922806","https://openalex.org/W2970922997","https://openalex.org/W2971294569","https://openalex.org/W2974260792","https://openalex.org/W2996500186","https://openalex.org/W3013207865","https://openalex.org/W3098430919"],"related_works":["https://openalex.org/W3172013301","https://openalex.org/W4399489031","https://openalex.org/W4327683235","https://openalex.org/W3035149581","https://openalex.org/W2942786103","https://openalex.org/W3003995118","https://openalex.org/W2967181322","https://openalex.org/W7199766672","https://openalex.org/W3139824234","https://openalex.org/W2993512619"],"abstract_inverted_index":{"Heart":[0],"failure":[1,52,87],"is":[2,38],"an":[3,13,137],"increasingly":[4],"frequent":[5],"medical":[6],"disorder":[7],"due":[8],"to":[9,48,72,76,99,106,118,158],"changing":[10],"demographics":[11],"in":[12,33,79,97,110,163,174,195],"ageing":[14],"society.":[15],"Therapeutic":[16],"algorithms":[17],"based":[18],"on":[19],"ACE-inhibitors,":[20],"beta":[21],"blockers":[22],"and":[23,54,66,70,75,92],"MRA":[24,192],"have":[25],"been":[26,104],"successfully":[27],"established":[28],"for":[29,62,84],"patients":[30,132],"with":[31,133,146],"HFrEF":[32,80,232,253],"the":[34,63,67,89,93,108,119,122,147,154],"past.":[35],"However,":[36],"mortality":[37],"still":[39],"very":[40],"high.":[41],"Therefore,":[42,151],"new":[43],"therapeutic":[44],"approaches":[45],"are":[46,88],"warranted":[47],"reduce":[49,73],"expensive":[50],"heart":[51,86],"hospitalizations":[53,74],"outcome.":[55],"Latest":[56],"data":[57,125],"suggest":[58],"a":[59,160],"substantial":[60],"benefit":[61],"ARNI":[64,218],"sacubitril/valsartan":[65],"SGLT2-inhibitors":[68],"dapagliflozin":[69],"empagliflozin":[71],"improve":[77,107],"outcome":[78,109],"patients.":[81,112],"New":[82,124],"candidates":[83],"advanced":[85],"myosin-activator":[90],"omecamtiv-mecarbil":[91],"guanylatcyclasestimulator":[94],"vericiguat.":[95],"Unfortunately,":[96],"contrast":[98],"HFrEF,":[100],"no":[101],"treatment":[102,164],"has":[103],"able":[105],"HFpEF":[111,134,166,287,311],"This":[113],"fact":[114],"might":[115],"be":[116,143],"related":[117],"heterogeneity":[120],"of":[121,130,153,165],"disease.":[123],"reveal":[126],"that":[127],"ca.":[128,281],"13%":[129],"all":[131],"suffer":[135],"from":[136],"underlying":[138,155],"ATTR":[139],"amyloidosis,":[140],"which":[141],"could":[142],"specifically":[144],"treated":[145],"tetramer":[148],"stabilizer":[149],"tafamidis.":[150],"differentiation":[152],"etiology":[156],"seems":[157],"play":[159],"crucial":[161],"role":[162],"patients.br":[167],"bKurzfassung:":[168],"/bAufgrund":[169],"der":[170,183,196,240,244,272,305,310],"sich":[171,194],"ver\u00e4ndernden":[172],"Demographie":[173],"einer":[175],"zunehmend":[176],"\u00e4lter":[177],"werdenden":[178],"Gesellschaft":[179],"nimmt":[180],"die":[181,223,269,292,303],"Pr\u00e4valenz":[182],"Herzinsuffizienz":[184,237],"deutlich":[185],"zu.":[186],"Behandlungsalgorithmen":[187],"mit":[188,231,286,294],"ACE-Hemmern,":[189],"Betablocker":[190],"und":[191,210,226,243],"haben":[193],"Vergangenheit":[197],"bei":[198,228,261,309],"HfrEF-Patienten":[199],"gut":[200],"bew\u00e4hrt,":[201],"jedoch":[202],"besteht":[203],"nach":[204],"wie":[205,220],"vor":[206],"eine":[207,233,289,315],"hohe":[208],"Morbidit\u00e4t":[209],"Sterblichkeit.":[211],"Neueste":[212],"Daten":[213,277],"zeigen":[214],"sowohl":[215],"fu\u0308r":[216,222],"den":[217],"Sacubitril/Valsartan":[219],"auch":[221],"SGLT2-Inhibitoren":[224],"Dapagliflozin":[225],"Empagliflozin":[227],"symptomatischen":[229],"Patienten":[230,285],"Prognoseverbesserung.":[234],"Bei":[235],"fortgeschrittener":[236],"k\u00f6nnten":[238],"zuku\u0308nftig":[239],"Myosin-Aktivator":[241],"Omecamtiv-Mecarbil":[242],"Guanylatcyclase-Stimulator":[245],"Vericiguat":[246],"weitere":[247],"Therapieoptionen":[248],"darstellen.":[249],"Im":[250],"Gegensatz":[251],"zur":[252],"konnte":[254],"bisher":[255],"leider":[256],"keine":[257],"Behandlung":[258,318],"das":[259],"Outcome":[260],"HfpEFPatienten":[262],"nachhaltig":[263],"verbessern.":[264],"Ein":[265],"Grund":[266],"hierfu\u0308r":[267],"k\u00f6nnte":[268],"heterogene":[270],"Population":[271],"HfpEF-Patienten":[273],"sein.":[274],"So":[275],"weisen":[276],"darauf":[278],"hin,":[279],"dass":[280],"13":[282],"%":[283],"aller":[284],"\u00e4tiologisch":[288],"ATTR-Amyloidose":[290],"aufweisen,":[291],"spezifisch":[293],"dem":[295],"Tetramerstabilisator":[296],"Tafamidis":[297],"behandelt":[298],"werden":[299],"kann.":[300],"Jedenfalls":[301],"scheint":[302],"Kl\u00e4rung":[304],"zugrunde":[306],"liegenden":[307],"\u00c4tiologie":[308],"sehr":[312],"wichtig,":[313],"um":[314],"zielgerichtete":[316],"pharmakologische":[317],"initiieren":[319],"zu":[320],"k\u00f6nnen.":[321]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3150895131","counts_by_year":[],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2021-04-13T00:00:00"}
